- Bora Pharmaceuticals has unveiled a new small molecule dose form manufacturing facility in Zhongli, Taiwan.
- The site expands Bora’s CDMO services, offering capabilities for complex tablets, capsules, and potent and hormonal products.
Bora Pharmaceuticals Co., Ltd., a global contract development and manufacturing organization (CDMO), has announced the grand opening of its new small molecule dose form manufacturing facility in Zhongli, Taiwan. This expansion marks a significant step in enhancing Bora’s ability to deliver advanced manufacturing solutions to its global clients.
The Zhongli site offers a wide range of manufacturing services, including the production of complex tablets and capsules. Notably, the facility is equipped with segregated areas specifically designed for potent and hormonal product manufacturing, ensuring safety and precision.
“We are excited to bring the know-how of our Zhongli team and such a strong site into the Bora CDMO network,” said J.D. Mowery, President of the CDMO Division at Bora Pharmaceuticals. “Leveraging the Bora culture, this facility will complement our extensive network in Taiwan and North America to serve our partners globally.”
